Attached files
| file | filename |
|---|---|
| EX-99.1 - Vicor Technologies, Inc. | v229951_ex99-1.htm |
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 27, 2011
VICOR TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
|
Delaware
|
000-51475
|
20-2903491
|
|
(State or other jurisdiction
|
(Commission
|
(IRS Employer
|
|
of Incorporation)
|
File Number)
|
Identification No.)
|
|
2300 Corporate Blvd., N.W., Suite 123
Boca Raton, Florida
|
33431
|
||
|
(Address of principal executive offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (561) 995-7313
NONE
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On July 27, 2011 Vicor Technologies, Inc. (the "Company") issued a press release announcing an agreement with Zoll Medical Corporation. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K.
Item 9.01 Financial Statements and Exhibits.
|
(d)
|
Exhibits.
|
|
99.1
|
Press Release dated July 27, 2011, issued by Vicor Technologies, Inc.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VICOR TECHNOLOGIES, INC.
|
||
|
Date: July 27, 2011
|
By:
|
/s/ David H. Fater
|
|
David H. Fater
|
||
|
President and Chief Executive
|
||
|
Officer
|
||